New European Monographs Set ‘Robust Standards’ For Biosimilar Development
Executive Summary
A European Pharmacopoeia pilot project has resulted in the establishment of monographs for a number of complex biotherapeutics that will set “robust” standards for the development of biosimilars in the future.
You may also be interested in...
European Pharmacopoeia Moves Forward With MAb Quality Standards
A pilot project run by the European Pharmacopoeia is being expanded in an effort to produce general quality standards for monoclonal antibodies, following the adoption of a monograph for infliximab last November.
Feel The Quality: Biosimilars Dominate Standards Setting Debate In EU
The quality issues that the European Medicines Agency considers when it evaluates biosimilar medicines became clearer during a recent event held in Strasbourg, France, where delegates also learned more about the role of European Pharmacopoeia monographs in ensuring the quality of biosimilars.
Feel The Quality: Biosimilars Dominate Standards Setting Debate In EU
The quality issues that the European Medicines Agency considers when it evaluates biosimilar medicines became clearer during a recent event held in Strasbourg, France, where delegates also learned more about the role of European Pharmacopoeia monographs in ensuring the quality of biosimilars.